Blog tagged as AI Validation

Moe Alsumidaie’s latest article explores how the updated ICH E6(R3) guidance raises the bar for imaging in clinical trials. With imaging as the primary endpoint in most oncology studies, sites and sponsors must now meet the same Good Clinical Practice (GCP) standards as other critical data types.

Imaging is essential to trials but remains one of the most broken workflows. Yunu CEO Jeff Sorenson shares how real-time, connected platforms improve accuracy, speed, and patient outcomes by replacing outdated imaging processes.

Emerging technologies are transforming pediatric oncology trials—boosting efficiency, protecting staff, and accelerating access to life-saving therapies through AI, real-world data, decentralized models, and digital tools.

This interview with Yunu CEO Jeffrey Sorenson explores how elevating imaging data in clinical trials can improve data integrity, trial efficiency, and patient outcomes, highlighting tech innovations and structural shifts needed for modern oncology research.

Dr. Harris, who has spent years at the forefront of imaging research at institutions like the Dana-Farber/Harvard Cancer Center and MGH, shared eye-opening insights into why clinical trial imaging is often broken and, more importantly, how Yunu is working to fix it.

Yunu is pleased to announce its partnership with WCG, a global leader in clinical trial solutions, in support of WCG’s imaging services.

Yunu is pleased to announce its partnership with WCG, a global leader in clinical trial solutions, in support of WCG’s imaging services.